Share this post on:



FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 02/2022”.

The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of February 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 1,661m so far
  • Top 5 Deals exceed EUR 60m each, largest transaction amounted to EUR 125m in Patient21 (Germany)
  • Curie Capital (Netherlands) dominates the Top 5 Investors (by deal volume), followed by Dompé (Italy) and Casdin Capital (United States)
  • The Biotech sector received 42% of the total investment volume (+7% points compared to the previous month)
  • Oncology dominates as the top indication of the Biotechnology sector

To access the full report, please click here.

By Dr. Mathias Schott and Sebastian Sommer




Source link

Share this post on:

Leave a Comment

Your email address will not be published. Required fields are marked *